| __timestamp | Geron Corporation | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20707000 | 45967000 |
| Thursday, January 1, 2015 | 17831000 | 114737000 |
| Friday, January 1, 2016 | 18047000 | 183204000 |
| Sunday, January 1, 2017 | 11033000 | 231644000 |
| Monday, January 1, 2018 | 13432000 | 293998000 |
| Tuesday, January 1, 2019 | 52072000 | 357355000 |
| Wednesday, January 1, 2020 | 51488000 | 412084000 |
| Friday, January 1, 2021 | 85727000 | 497153000 |
| Saturday, January 1, 2022 | 95518000 | 705789000 |
| Sunday, January 1, 2023 | 125046000 | 648449000 |
In pursuit of knowledge
In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Ultragenyx Pharmaceutical Inc. and Geron Corporation have demonstrated contrasting trajectories in their R&D investments.
From 2014 to 2023, Ultragenyx has consistently outpaced Geron, with its R&D expenses growing by over 1,300%, peaking in 2022. This surge underscores Ultragenyx's aggressive pursuit of groundbreaking therapies. In contrast, Geron's R&D spending, while increasing by approximately 500% over the same period, reflects a more measured approach.
The data reveals a pivotal moment in 2019 when Geron significantly ramped up its R&D budget, marking a strategic shift. As the biotech industry continues to expand, these spending patterns offer valuable insights into each company's strategic priorities and potential future breakthroughs.
R&D Insights: How Sanofi and Geron Corporation Allocate Funds
Research and Development: Comparing Key Metrics for GSK plc and Ultragenyx Pharmaceutical Inc.
Comparing Innovation Spending: United Therapeutics Corporation and Ultragenyx Pharmaceutical Inc.
Research and Development: Comparing Key Metrics for Genmab A/S and Geron Corporation
Research and Development: Comparing Key Metrics for Incyte Corporation and Geron Corporation
Research and Development Investment: Summit Therapeutics Inc. vs Geron Corporation
Research and Development Investment: Ultragenyx Pharmaceutical Inc. vs CRISPR Therapeutics AG
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs MorphoSys AG
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs Viridian Therapeutics, Inc.
Rhythm Pharmaceuticals, Inc. vs Geron Corporation: Strategic Focus on R&D Spending
Analyzing R&D Budgets: HUTCHMED (China) Limited vs Geron Corporation
Research and Development Expenses Breakdown: Arrowhead Pharmaceuticals, Inc. vs Geron Corporation